(Q30452150)

21 June 2017

title

Management of mantle cell lymphoma: key challenges and next steps (English)

1 reference

21 June 2017

Management of Mantle Cell Lymphoma: Key Challenges and Next Steps (English)

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

16 August 2024

1 reference

2

Martin Dreyling

1 reference

21 June 2017

Jane Winter

3

1 reference

21 June 2017

Sabeeha Muneer

4

1 reference

21 June 2017

Michael E. Williams

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21030346

16 August 2024

John P. Leonard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21030346

16 August 2024

language of work or name

English

0 references

publication date

1 October 2010

1 reference

full work available at URL

21 June 2017

https://api.elsevier.com/content/article/PII:S2152265011701999?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

https://api.elsevier.com/content/article/PII:S2152265011701999?httpAccept=text/plain

16 August 2024

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Clinical Lymphoma, Myeloma & Leukemia

16 August 2024

published in

1 reference

21 June 2017

volume

10

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

336-346

1 reference

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

21 June 2017

cites work

1

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma

16 August 2024

3

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

16 August 2024

6

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

16 August 2024

7

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

The Tak-1 Inhibitor AZ-Tak1 Inhibits XIAP, Activates Caspase-9, and Induces Apoptosis in Mantle Cell Lymphoma.

16 August 2024

8

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.

16 August 2024

12

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.

16 August 2024

13

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).

16 August 2024

14

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

16 August 2024

15

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

16 August 2024

16

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Tumour-educated macrophages promote tumour progression and metastasis

16 August 2024

17

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Immunophenotypic variations in mantle cell lymphoma

16 August 2024

18

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

16 August 2024

19

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

16 August 2024

22

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

16 August 2024

24

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

16 August 2024

25

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma

16 August 2024

26

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

16 August 2024

27

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

16 August 2024

29

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

16 August 2024

30

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Current treatment standards and emerging strategies in mantle cell lymphoma

16 August 2024

31

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group

16 August 2024

32

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

16 August 2024

33

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

16 August 2024

34

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

16 August 2024

35

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

16 August 2024

36

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network

16 August 2024

38

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

16 August 2024

39

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

16 August 2024

40

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.

16 August 2024

41

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

16 August 2024

44

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

16 August 2024

45

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

16 August 2024

48

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

16 August 2024

49

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

16 August 2024

51

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

16 August 2024

52

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

First Line Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma (MCL).

16 August 2024

55

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

16 August 2024

56

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

16 August 2024

58

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Proteasome inhibitors in the treatment of multiple myeloma

16 August 2024

61

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

16 August 2024

62

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells

16 August 2024

63

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

16 August 2024

64

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors

16 August 2024

65

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

16 August 2024

66

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

16 August 2024

67

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

16 August 2024

68

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

16 August 2024

70

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

16 August 2024

72

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Bendamustine: rebirth of an old drug

16 August 2024

74

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

16 August 2024

75

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

16 August 2024

76

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

16 August 2024

77

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Mechanism of action of lenalidomide in hematological malignancies

16 August 2024

79

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

16 August 2024

80

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

16 August 2024

81

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma.

16 August 2024

85

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

16 August 2024

88

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

16 August 2024

89

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

16 August 2024

90

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

16 August 2024

91

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

16 August 2024

92

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

16 August 2024

94

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

16 August 2024

95

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

16 August 2024

96

1 reference

https://api.crossref.org/works/10.3816/CLML.2010.N.066

16 August 2024

Identifiers

1 reference

21 June 2017

1 reference